BioLineRx (BLRX) Scheduled to Post Earnings on Thursday

BioLineRx (NASDAQ:BLRX) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, August 15th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Tuesday, May 28th. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.28. The company had revenue of $6.86 million during the quarter, compared to the consensus estimate of $0.34 million. During the same period last year, the business earned ($0.15) EPS. On average, analysts expect BioLineRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioLineRx Price Performance

BLRX traded up $0.04 on Friday, hitting $0.72. 28,400 shares of the company’s stock traded hands, compared to its average volume of 366,609. The company’s 50 day simple moving average is $0.68 and its 200-day simple moving average is $0.86. The firm has a market cap of $57.55 million, a price-to-earnings ratio of -0.95 and a beta of 1.52. BioLineRx has a one year low of $0.51 and a one year high of $2.53. The company has a current ratio of 1.14, a quick ratio of 1.05 and a debt-to-equity ratio of 0.45.

Wall Street Analyst Weigh In

BLRX has been the topic of a number of research reports. StockNews.com raised BioLineRx from a “sell” rating to a “hold” rating in a research note on Monday, June 3rd. HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of BioLineRx in a report on Wednesday, May 29th.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.